Company / Gross Margin
NeoGenomics Laboratories, Inc. Gross Margin History
FY2016-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
165.3%
FY2017
5-year range
-
FY2016-FY2017
Trend
+311.3%
vs FY2016
Sector context
#1 of 96
Health Care
What the data says
Among 96 Health Care companies, NeoGenomics Laboratories, Inc. is in the top 1% for gross margin.
Based on SEC 10-K filings.
165.3% in FY2017. Ranks 1st among 96 companies in Health Care.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Top 1% in Health CareTop 1% of 96This company 165.3% Sector average 53.6%
▼
+208.5% above sector average
Key checks
Key Insights
- In FY2017, gross margin increased 311.3% year-over-year.
- Currently 111.7pp above the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | 165.3% | +311.3% |
| FY2016 | 40.2% | -95.4% |
As of FY2017 · SEC 10-K · Updated Jun 30, 2026